Amla for Health & Longevity

Created on 10/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Amla, a sour Asian fruit from traditional Indian medicine sold as powders and extracts, is studied mainly for blood fats and blood sugar. Small, mostly maker-funded trials suggest a modest, product-dependent drop in harmful cholesterol and blood fats. Side effects are mostly mild indigestion; concerns are possible added bleeding with anti-clotting medication, extra blood-sugar lowering with diabetes drugs, and uneven quality. Long-term safety is unknown; no lifespan benefit is established. (Full Review)

Protocol

Aqueous tannin extract (Capros)
500 mg twice daily
12 weeks, the most-tested regimen; 250 mg twice daily was less effective
Whole-fruit ethyl-acetate extract (AMX-160)
500 mg twice daily
After breakfast and dinner for 12 weeks
Dried fruit powder
1–3 g daily
Or 500 mg three times daily after meals in hypertension
Time to effect
Lipids
4–12 weeks
LDL cholesterol and triglyceride changes
Glucose
4–12 weeks
Blood-sugar changes
Reflux symptoms
2 and 4 weeks
Points at which symptoms were assessed

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • People with bleeding disorders or active bleeding (theoretical)
  • People scheduled for surgery or invasive dental work (theoretical)
  • People with known allergy to amla or Triphala products
Key Interactions
  • Antiplatelet drugs (clopidogrel, aspirin): Caution; increased bleeding risk
  • Anticoagulants (warfarin, apixaban): Caution (theoretical); increased bleeding risk
  • Glucose-lowering drugs (insulin; sulfonylureas such as glimepiride): Monitor; possible low blood sugar (theoretical)
  • Antihypertensives (amlodipine, enalapril): Monitor; possible lower pressure
  • Statins (atorvastatin, rosuvastatin): Monitor (theoretical); larger lipid change
  • Over-the-counter NSAIDs (ibuprofen, naproxen): Caution (theoretical); additive bleeding and indigestion risk
  • Anticholinergic drugs (atropine, benztropine): Monitor (theoretical); altered drug effect
  • Supplements with antiplatelet effects (fish oil, garlic): Caution (theoretical); increased bleeding risk
  • Supplements with glucose-lowering effects (berberine, cinnamon): Monitor (theoretical); low blood sugar in people on diabetes drugs
  • Supplements with lipid-lowering effects (red yeast rice, plant sterols): Monitor (theoretical); larger lipid change
  • Iron supplements (ferrous sulfate, ferrous bisglycinate): Monitor (theoretical); uncertain iron uptake
  • Other oral medications and health products: Monitor; possibly altered uptake (theoretical)

Risk & Side Effects

  • High:
  • Medium: Mild gastrointestinal upset
  • Low: Low blood sugar with glucose-lowering drugs; contamination and mislabeling; allergic skin reactions
  • Speculative: Increased bleeding tendency; reduced iron absorption; kidney stone formation

Monitoring

Marker Target Why
LDL cholesterol <100 mg/dL Main efficacy marker
Triglycerides <150 mg/dL Expected to change
Fasting glucose 70–99 mg/dL Efficacy; low-sugar safety check with diabetes drugs
HbA1c 4.0–5.6% Efficacy in diabetes; over-treatment check
hs-CRP 0.0–3.0 mg/L Inflammation (unvalidated marker)
INR (warfarin users only) Prescriber's therapeutic range Safety check; a rise changes use
Blood pressure Not specified in the ER Baseline record

Cadence: Baseline; lipids, glucose and HbA1c at 8–12 weeks, then every 6–12 months; glucose more often in the first 4 weeks on glucose-lowering drugs; INR within 1–2 weeks of starting in warfarin users

Qualitative Assessment

  • Digestive comfort: indigestion, constipation, loose stools, or changes in heartburn and regurgitation
  • Bleeding signs: new bruising, nosebleeds, gum bleeding, or heavier menstrual bleeding
  • Low-sugar symptoms in people on diabetes drugs: shakiness, sweating, sudden hunger, or confusion
  • Hair shedding and density, for those using amla for hair thinning